Innate Pharma (XPAR:IPH) Other Gross PPE : €5.75 Mil (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Other Gross PPE?

Innate Pharma's Other Gross PPE for the quarter that ended in Jun. 2024 was €5.75 Mil.

Innate Pharma's quarterly Other Gross PPE declined from Jun. 2023 (€7.26 Mil) to Dec. 2023 (€6.32 Mil) and declined from Dec. 2023 (€6.32 Mil) to Jun. 2024 (€5.75 Mil).

Innate Pharma's annual Other Gross PPE declined from Dec. 2021 (€10.17 Mil) to Dec. 2022 (€8.54 Mil) and declined from Dec. 2022 (€8.54 Mil) to Dec. 2023 (€6.32 Mil).

Innate Pharma Other Gross PPE Historical Data

The historical data trend for Innate Pharma's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Other Gross PPE Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

Get a 7-Day Free Trial

11.30

11.33

10.17

8.54

6.32

Innate Pharma Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Gross PPE	Get a 7-Day Free Trial															9.55	8.54	7.26	6.32	5.75

Innate Pharma Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Innate Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

IPHA:USA 0EVI:UK IDD:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines